Kallmann syndrome: Diagnostics and management

•Germline mutations in KAL1, is associated with Kallmann syndrome [MIM# 308700].•Germline mutations in KAL1 are extremely rare and till date very few mutations have been identified and reported worldwide.•Till date, no comprehensive review on genetic diagnostics and disease management of Kallmann Sy...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinica chimica acta 2025-01, Vol.565, p.119994, Article 119994
Hauptverfasser: Kumar Yadav, Rajiv, Qi, Baiyu, Wen, Jianping, Gang, Xiaokun, Banerjee, Santasree
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page 119994
container_title Clinica chimica acta
container_volume 565
creator Kumar Yadav, Rajiv
Qi, Baiyu
Wen, Jianping
Gang, Xiaokun
Banerjee, Santasree
description •Germline mutations in KAL1, is associated with Kallmann syndrome [MIM# 308700].•Germline mutations in KAL1 are extremely rare and till date very few mutations have been identified and reported worldwide.•Till date, no comprehensive review on genetic diagnostics and disease management of Kallmann Syndrome have been reported. Kallmann syndrome is a genetic disorder characterized by delayed or absence of puberty and a reduced or absent sense of smell (anosmia). Kallmann syndrome is a form of hypogonadotropic hypogonadism due to lack of the production of sex hormones which is associated with development of secondary sexual characteristics. Kallmann Syndrome is a genetically heterogeneous disorder, characterized by the combination of hypogonadotropic hypogonadism (a deficiency in sex hormone production) and anosmia. Germline mutations in KAL1 gene causes deficiency in GnRH hormone followed by low level of circulating gonadotropin and testosterone which finally leads to the failure of puberty (development of secondary sexual characters). Kallmann Syndrome can be inherited in several manners including X-linked recessive (e.g., mutations within KAL1) and autosomal dominant and recessive forms. Germline mutation in KAL1 gene was identified among 8% of patients with Kallmann Syndrome. A review of the recent literature done reveals numerous clinical manifestations in Kallmann Syndrome patients with the KAL1 mutation, including microgenitalia, impotence, reduced libido, infertility, unilateral renal agenesis, and synkinesia. Genetic molecular diagnostics through prenatal diagnosis and preimplantation genetic testing are most significant way to reduce the risk of Kallmann syndrome in next generation. Complication associated with Kallmann syndrome can be prevented by early diagnosis, diet supplementation and medical therapy. Goal of therapeutic intervention is to the development of secondary sexual characteristics, build and sustain bone density as well as muscle mass and restore fertility. This review aims to explore the genetic diagnosis and management strategies for Kallmann Syndrome, particularly focusing on KAL1 gene mutations.
doi_str_mv 10.1016/j.cca.2024.119994
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3115094240</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0009898124022472</els_id><sourcerecordid>3115094240</sourcerecordid><originalsourceid>FETCH-LOGICAL-c235t-f95120400c66e1e5d0af3e8b92422944306d51291b784149578f6d45f984fc563</originalsourceid><addsrcrecordid>eNp9kL1OwzAURi0EoqXwACwoI0uKr-2kMUyo_IpKLDBbrn1TuUqcYqdIfXtcpTAyXVn3fJ_tQ8gl0ClQKG_WU2P0lFEmpgBSSnFExlDNeM6FZMdkTCmVeSUrGJGzGNfpKGgJp2TEJa8EMDkm-ZtumlZ7n8Wdt6Fr8TZ7cHrlu9g7EzPtbZbWeoUt-v6cnNS6iXhxmBPy-fT4MX_JF-_Pr_P7RW4YL_q8lgWwdBc1ZYmAhaW65lgtJROMSSE4LW0iJCxn6RlCFrOqLq0oalmJ2hQln5DroXcTuq8txl61LhpsGu2x20bFAQoqBRM0oTCgJnQxBqzVJrhWh50CqvaW1FolS2pvSQ2WUubqUL9dtmj_Er9aEnA3AJg--e0wqGgceoPWBTS9sp37p_4HQtF0mg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3115094240</pqid></control><display><type>article</type><title>Kallmann syndrome: Diagnostics and management</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Kumar Yadav, Rajiv ; Qi, Baiyu ; Wen, Jianping ; Gang, Xiaokun ; Banerjee, Santasree</creator><creatorcontrib>Kumar Yadav, Rajiv ; Qi, Baiyu ; Wen, Jianping ; Gang, Xiaokun ; Banerjee, Santasree</creatorcontrib><description>•Germline mutations in KAL1, is associated with Kallmann syndrome [MIM# 308700].•Germline mutations in KAL1 are extremely rare and till date very few mutations have been identified and reported worldwide.•Till date, no comprehensive review on genetic diagnostics and disease management of Kallmann Syndrome have been reported. Kallmann syndrome is a genetic disorder characterized by delayed or absence of puberty and a reduced or absent sense of smell (anosmia). Kallmann syndrome is a form of hypogonadotropic hypogonadism due to lack of the production of sex hormones which is associated with development of secondary sexual characteristics. Kallmann Syndrome is a genetically heterogeneous disorder, characterized by the combination of hypogonadotropic hypogonadism (a deficiency in sex hormone production) and anosmia. Germline mutations in KAL1 gene causes deficiency in GnRH hormone followed by low level of circulating gonadotropin and testosterone which finally leads to the failure of puberty (development of secondary sexual characters). Kallmann Syndrome can be inherited in several manners including X-linked recessive (e.g., mutations within KAL1) and autosomal dominant and recessive forms. Germline mutation in KAL1 gene was identified among 8% of patients with Kallmann Syndrome. A review of the recent literature done reveals numerous clinical manifestations in Kallmann Syndrome patients with the KAL1 mutation, including microgenitalia, impotence, reduced libido, infertility, unilateral renal agenesis, and synkinesia. Genetic molecular diagnostics through prenatal diagnosis and preimplantation genetic testing are most significant way to reduce the risk of Kallmann syndrome in next generation. Complication associated with Kallmann syndrome can be prevented by early diagnosis, diet supplementation and medical therapy. Goal of therapeutic intervention is to the development of secondary sexual characteristics, build and sustain bone density as well as muscle mass and restore fertility. This review aims to explore the genetic diagnosis and management strategies for Kallmann Syndrome, particularly focusing on KAL1 gene mutations.</description><identifier>ISSN: 0009-8981</identifier><identifier>ISSN: 1873-3492</identifier><identifier>EISSN: 1873-3492</identifier><identifier>DOI: 10.1016/j.cca.2024.119994</identifier><identifier>PMID: 39384129</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Extracellular Matrix Proteins - genetics ; Gonadotropic-releasing hormone ; Humans ; Hypogonadotropic hypogonadism ; KAL1 gene ; Kallmann syndrome ; Kallmann Syndrome - diagnosis ; Kallmann Syndrome - genetics ; Kallmann Syndrome - therapy ; Mutation ; Preimplantation genetic testing ; Prenatal diagnosis</subject><ispartof>Clinica chimica acta, 2025-01, Vol.565, p.119994, Article 119994</ispartof><rights>2024 Elsevier B.V.</rights><rights>Copyright © 2024 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c235t-f95120400c66e1e5d0af3e8b92422944306d51291b784149578f6d45f984fc563</cites><orcidid>0000-0003-2481-4562</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.cca.2024.119994$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39384129$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kumar Yadav, Rajiv</creatorcontrib><creatorcontrib>Qi, Baiyu</creatorcontrib><creatorcontrib>Wen, Jianping</creatorcontrib><creatorcontrib>Gang, Xiaokun</creatorcontrib><creatorcontrib>Banerjee, Santasree</creatorcontrib><title>Kallmann syndrome: Diagnostics and management</title><title>Clinica chimica acta</title><addtitle>Clin Chim Acta</addtitle><description>•Germline mutations in KAL1, is associated with Kallmann syndrome [MIM# 308700].•Germline mutations in KAL1 are extremely rare and till date very few mutations have been identified and reported worldwide.•Till date, no comprehensive review on genetic diagnostics and disease management of Kallmann Syndrome have been reported. Kallmann syndrome is a genetic disorder characterized by delayed or absence of puberty and a reduced or absent sense of smell (anosmia). Kallmann syndrome is a form of hypogonadotropic hypogonadism due to lack of the production of sex hormones which is associated with development of secondary sexual characteristics. Kallmann Syndrome is a genetically heterogeneous disorder, characterized by the combination of hypogonadotropic hypogonadism (a deficiency in sex hormone production) and anosmia. Germline mutations in KAL1 gene causes deficiency in GnRH hormone followed by low level of circulating gonadotropin and testosterone which finally leads to the failure of puberty (development of secondary sexual characters). Kallmann Syndrome can be inherited in several manners including X-linked recessive (e.g., mutations within KAL1) and autosomal dominant and recessive forms. Germline mutation in KAL1 gene was identified among 8% of patients with Kallmann Syndrome. A review of the recent literature done reveals numerous clinical manifestations in Kallmann Syndrome patients with the KAL1 mutation, including microgenitalia, impotence, reduced libido, infertility, unilateral renal agenesis, and synkinesia. Genetic molecular diagnostics through prenatal diagnosis and preimplantation genetic testing are most significant way to reduce the risk of Kallmann syndrome in next generation. Complication associated with Kallmann syndrome can be prevented by early diagnosis, diet supplementation and medical therapy. Goal of therapeutic intervention is to the development of secondary sexual characteristics, build and sustain bone density as well as muscle mass and restore fertility. This review aims to explore the genetic diagnosis and management strategies for Kallmann Syndrome, particularly focusing on KAL1 gene mutations.</description><subject>Extracellular Matrix Proteins - genetics</subject><subject>Gonadotropic-releasing hormone</subject><subject>Humans</subject><subject>Hypogonadotropic hypogonadism</subject><subject>KAL1 gene</subject><subject>Kallmann syndrome</subject><subject>Kallmann Syndrome - diagnosis</subject><subject>Kallmann Syndrome - genetics</subject><subject>Kallmann Syndrome - therapy</subject><subject>Mutation</subject><subject>Preimplantation genetic testing</subject><subject>Prenatal diagnosis</subject><issn>0009-8981</issn><issn>1873-3492</issn><issn>1873-3492</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2025</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kL1OwzAURi0EoqXwACwoI0uKr-2kMUyo_IpKLDBbrn1TuUqcYqdIfXtcpTAyXVn3fJ_tQ8gl0ClQKG_WU2P0lFEmpgBSSnFExlDNeM6FZMdkTCmVeSUrGJGzGNfpKGgJp2TEJa8EMDkm-ZtumlZ7n8Wdt6Fr8TZ7cHrlu9g7EzPtbZbWeoUt-v6cnNS6iXhxmBPy-fT4MX_JF-_Pr_P7RW4YL_q8lgWwdBc1ZYmAhaW65lgtJROMSSE4LW0iJCxn6RlCFrOqLq0oalmJ2hQln5DroXcTuq8txl61LhpsGu2x20bFAQoqBRM0oTCgJnQxBqzVJrhWh50CqvaW1FolS2pvSQ2WUubqUL9dtmj_Er9aEnA3AJg--e0wqGgceoPWBTS9sp37p_4HQtF0mg</recordid><startdate>20250115</startdate><enddate>20250115</enddate><creator>Kumar Yadav, Rajiv</creator><creator>Qi, Baiyu</creator><creator>Wen, Jianping</creator><creator>Gang, Xiaokun</creator><creator>Banerjee, Santasree</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-2481-4562</orcidid></search><sort><creationdate>20250115</creationdate><title>Kallmann syndrome: Diagnostics and management</title><author>Kumar Yadav, Rajiv ; Qi, Baiyu ; Wen, Jianping ; Gang, Xiaokun ; Banerjee, Santasree</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c235t-f95120400c66e1e5d0af3e8b92422944306d51291b784149578f6d45f984fc563</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2025</creationdate><topic>Extracellular Matrix Proteins - genetics</topic><topic>Gonadotropic-releasing hormone</topic><topic>Humans</topic><topic>Hypogonadotropic hypogonadism</topic><topic>KAL1 gene</topic><topic>Kallmann syndrome</topic><topic>Kallmann Syndrome - diagnosis</topic><topic>Kallmann Syndrome - genetics</topic><topic>Kallmann Syndrome - therapy</topic><topic>Mutation</topic><topic>Preimplantation genetic testing</topic><topic>Prenatal diagnosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kumar Yadav, Rajiv</creatorcontrib><creatorcontrib>Qi, Baiyu</creatorcontrib><creatorcontrib>Wen, Jianping</creatorcontrib><creatorcontrib>Gang, Xiaokun</creatorcontrib><creatorcontrib>Banerjee, Santasree</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinica chimica acta</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kumar Yadav, Rajiv</au><au>Qi, Baiyu</au><au>Wen, Jianping</au><au>Gang, Xiaokun</au><au>Banerjee, Santasree</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Kallmann syndrome: Diagnostics and management</atitle><jtitle>Clinica chimica acta</jtitle><addtitle>Clin Chim Acta</addtitle><date>2025-01-15</date><risdate>2025</risdate><volume>565</volume><spage>119994</spage><pages>119994-</pages><artnum>119994</artnum><issn>0009-8981</issn><issn>1873-3492</issn><eissn>1873-3492</eissn><abstract>•Germline mutations in KAL1, is associated with Kallmann syndrome [MIM# 308700].•Germline mutations in KAL1 are extremely rare and till date very few mutations have been identified and reported worldwide.•Till date, no comprehensive review on genetic diagnostics and disease management of Kallmann Syndrome have been reported. Kallmann syndrome is a genetic disorder characterized by delayed or absence of puberty and a reduced or absent sense of smell (anosmia). Kallmann syndrome is a form of hypogonadotropic hypogonadism due to lack of the production of sex hormones which is associated with development of secondary sexual characteristics. Kallmann Syndrome is a genetically heterogeneous disorder, characterized by the combination of hypogonadotropic hypogonadism (a deficiency in sex hormone production) and anosmia. Germline mutations in KAL1 gene causes deficiency in GnRH hormone followed by low level of circulating gonadotropin and testosterone which finally leads to the failure of puberty (development of secondary sexual characters). Kallmann Syndrome can be inherited in several manners including X-linked recessive (e.g., mutations within KAL1) and autosomal dominant and recessive forms. Germline mutation in KAL1 gene was identified among 8% of patients with Kallmann Syndrome. A review of the recent literature done reveals numerous clinical manifestations in Kallmann Syndrome patients with the KAL1 mutation, including microgenitalia, impotence, reduced libido, infertility, unilateral renal agenesis, and synkinesia. Genetic molecular diagnostics through prenatal diagnosis and preimplantation genetic testing are most significant way to reduce the risk of Kallmann syndrome in next generation. Complication associated with Kallmann syndrome can be prevented by early diagnosis, diet supplementation and medical therapy. Goal of therapeutic intervention is to the development of secondary sexual characteristics, build and sustain bone density as well as muscle mass and restore fertility. This review aims to explore the genetic diagnosis and management strategies for Kallmann Syndrome, particularly focusing on KAL1 gene mutations.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>39384129</pmid><doi>10.1016/j.cca.2024.119994</doi><orcidid>https://orcid.org/0000-0003-2481-4562</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0009-8981
ispartof Clinica chimica acta, 2025-01, Vol.565, p.119994, Article 119994
issn 0009-8981
1873-3492
1873-3492
language eng
recordid cdi_proquest_miscellaneous_3115094240
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects Extracellular Matrix Proteins - genetics
Gonadotropic-releasing hormone
Humans
Hypogonadotropic hypogonadism
KAL1 gene
Kallmann syndrome
Kallmann Syndrome - diagnosis
Kallmann Syndrome - genetics
Kallmann Syndrome - therapy
Mutation
Preimplantation genetic testing
Prenatal diagnosis
title Kallmann syndrome: Diagnostics and management
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T11%3A34%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Kallmann%20syndrome:%20Diagnostics%20and%20management&rft.jtitle=Clinica%20chimica%20acta&rft.au=Kumar%20Yadav,%20Rajiv&rft.date=2025-01-15&rft.volume=565&rft.spage=119994&rft.pages=119994-&rft.artnum=119994&rft.issn=0009-8981&rft.eissn=1873-3492&rft_id=info:doi/10.1016/j.cca.2024.119994&rft_dat=%3Cproquest_cross%3E3115094240%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3115094240&rft_id=info:pmid/39384129&rft_els_id=S0009898124022472&rfr_iscdi=true